Present and Future Treatment of Myasthenia Gravis

Research output: Contribution to journalEditorialpeer-review

Abstract

More than half a century ago, Mary Walker — a registrar in an obscure outlying London hospital—carried out a nonrandomized, nonblinded, uncontrolled, but highly successful trial of physostigmine in a patient with myasthenia gravis. Hailed in the press as the “Miracle of St. Alfege's Hospital,” her discovery of the beneficial effect of this anticholinesterase agent provided evidence for a defect of neuromuscular transmission in myasthenia gravis and led to the use of similar drugs in the treatment of the disease. Since that time, and particularly during the past 15 years, knowledge of the pathophysiology of myasthenia gravis and its treatment.

Original languageEnglish (US)
Pages (from-to)743-745
Number of pages3
JournalNew England Journal of Medicine
Volume316
Issue number12
DOIs
StatePublished - Mar 19 1987

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Present and Future Treatment of Myasthenia Gravis'. Together they form a unique fingerprint.

Cite this